Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

This study tests the combination of two targeted drugs — dabrafenib and trametinib — plus radiation therapy in patients with anaplastic thyroid cancer (a rare, very aggressive thyroid cancer) that carries a specific genetic mutation called BRAF V600E or V600K. **You may be eligible if...** - You have been diagnosed with anaplastic thyroid cancer - Your tumor has a BRAF V600E or V600K mutation - Your general health level is adequate (ECOG less than 2) - Your blood counts (neutrophils, hemoglobin) meet minimum thresholds **You may NOT be eligible if...** - Your tumor does not have a BRAF mutation - Your blood counts are too low - Your overall health is too poor for treatment Talk to your doctor to see if this trial is right for you.